Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Up 7.5% in April

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 3,600,000 shares, an increase of 7.5% from the March 31st total of 3,350,000 shares. Based on an average daily volume of 348,900 shares, the short-interest ratio is presently 10.3 days.

Ascendis Pharma A/S Stock Up 0.7 %

Shares of ASND traded up $0.99 during mid-day trading on Wednesday, hitting $139.43. 65,859 shares of the company’s stock were exchanged, compared to its average volume of 360,605. The stock’s 50-day simple moving average is $147.78 and its 200-day simple moving average is $127.09. The firm has a market cap of $8.12 billion, a price-to-earnings ratio of -14.96 and a beta of 0.50. Ascendis Pharma A/S has a 52 week low of $83.75 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. Analysts forecast that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $25,000. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter valued at about $36,000. Quadrant Capital Group LLC increased its position in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares in the last quarter. Finally, Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 31.9% during the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 193 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, April 18th. Finally, Wedbush raised their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.